TNFRSF17 and Miyoshi myopathy: Additionally, a phase 1 trial (NCT04108195) testing combinations of daratumumab with JNJ-64407564 (anti-GPRC5D BsAb) or JNJ-64007957 (anti-BCMA BsAb) in MM patients started in January 2020.